Rabbit Recombinant Monoclonal Tyrosinase antibody. Suitable for IHC-P, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human, Mouse samples. Cited in 22 publications.
pH: 7.2 - 7.4
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.35% Sodium citrate, 0.17% Sodium chloride, 0.05% BSA, 0.03% EDTA
IHC-P | IP | WB | ICC/IF | Flow Cyt (Intra) | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Tested | Tested | Tested |
Mouse | Not recommended | Not recommended | Tested | Expected | Expected |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/500 | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info - | Notes Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info 1/1000 - 1/5000 | Notes - |
Species Human | Dilution info 1/1000 - 1/5000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/50 - 1/100 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/30 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse | Dilution info Use at an assay dependent concentration. | Notes - |
Select an associated product type
This is a copper-containing oxidase that functions in the formation of pigments such as melanins and other polyphenolic compounds. Catalyzes the initial and rate limiting step in the cascade of reactions leading to melanin production from tyrosine (By similarity). In addition to hydroxylating tyrosine to DOPA (3,4-dihydroxyphenylalanine), also catalyzes the oxidation of DOPA to DOPA-quinone, and possibly the oxidation of DHI (5,6-dihydroxyindole) to indole-5,6 quinone (PubMed:28661582).
Tyrosinase, LB24-AB, Monophenol monooxygenase, SK29-AB, Tumor rejection antigen AB, TYR
Rabbit Recombinant Monoclonal Tyrosinase antibody. Suitable for IHC-P, WB, ICC/IF, Flow Cyt (Intra) and reacts with Human, Mouse samples. Cited in 22 publications.
pH: 7.2 - 7.4
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.35% Sodium citrate, 0.17% Sodium chloride, 0.05% BSA, 0.03% EDTA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Tyrosinase also known as monophenol monooxygenase is a copper-containing enzyme with a mass of approximately 60-70 kDa. It catalyzes the oxidation of phenols such as tyrosine to quinones which are important precursors for melanin synthesis. Tyrosinase is predominantly expressed in melanocytes the cells responsible for pigment production in skin hair and eyes. Its expression also occurs in other tissues like the brain where it might play different roles.
Within melanin production tyrosinase functions as the rate-limiting enzyme initiating the synthesis path by converting tyrosine into dopaquinone. This enzyme works as part of the melanogenic complex interacting with other enzymes such as tyrosinase-related proteins 1 and 2 to regulate melanin synthesis. The presence and activity of tyrosinase significantly impacts pigmentation processes and skin coloration.
Relating tyrosinase to melanin biosynthetic and regulatory pathways reveal its central role. The enzyme is vital in the Raper-Mason pathway for melanin production where it interacts with proteins such as dopachrome tautomerase. It bridges the gap between external stimuli like UV radiation and cellular responses transforming them into pigmentation changes. The L-tyrosine and catecholamine biosynthesis pathways also influence tyrosinase activity linking it to broader metabolic processes.
Issues with tyrosinase can lead to conditions like albinism and melanoma. In oculocutaneous albinism type 1 (OCA1) a genetic mutation in the tyrosinase gene results in reduced or absent enzymatic activity causing hypopigmentation. In melanoma abnormal regulation of tyrosinase and its pathway associates with tumor progression and metastasis often in connection with factors such as microphthalmia-associated transcription factor (MITF) that modulate its expression.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Immunohistochemical analysis of paraffin-embedded Human melanoma tissue, labeling Tyrosinase using ab170905 at a 1/100 dilution.
Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.
ab170905 staining Tyrosinase in A375 (human malignant melanoma) cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 100% methanol and incubated with primary antibody at a dilution of 1/500. A goat anti rabbit IgG (Alexa Fluor® 488) (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) was used as the secondary antibody at a dilution of 1/1000. DAPI was used as a nuclear counterstain.
Control: PBS only.
Exposure:
Lane 1: 20 seconds
Lane 2: 60 seconds
All lanes: Western blot - Anti-Tyrosinase antibody [EPR10141] (ab170905) at 1/1000 dilution
Lane 1: SK-MEL-28 (Human malignant melanoma) whole cell lysate at 15 µg
Lane 2: MeWo (Human malignant melanoma fibroblast) whole cell lysate at 15 µg
All lanes: Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 60 kDa
Observed band size: 70 kDa
All lanes: Western blot - Anti-Tyrosinase antibody [EPR10141] (ab170905) at 1/1000 dilution
All lanes: Human melanoma lysate at 10 µg
All lanes: Goat anti-rabbit HRP at 1/2000 dilution
Developed using the ECL technique.
Predicted band size: 60 kDa
Intracellular Flow Cytometry analysis of A375 (human malignant melanoma) cells labeling with purified ab170905 at 1/30 dilution (10ug/ml) (red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. A Goat anti rabbit IgG (Alexa Fluor® 488) (Goat Anti-Rabbit IgG H&L (Alexa Fluor® 488) ab150077) (1/2000 dilution) was used as the secondary antibody. Cells without incubation with primary antibody and secondary antibody (Blue) were used as unlabeled control.
Immunohistochemical analysis of paraffin-embedded human skin tissue labelling Tyrosinase with ab170905 at 1/500 (0.662 μg/ml) dilution followed by a ready to use LeicaDS9800 (Bond™ Polymer Refine Detection). Positive staining on human skin. The section was incubated with ab170905 for 30 mins at room temperature. The immunostaining was performed on a Leica Biosystems BOND® RX instrument. Counterstained with hematoxylin.
Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0, epitope retrieval solution2) for 20 mins.
Blocking buffer and concentration: 5% NFDM/TBST
Diluting buffer and concentration: 5% NFDM/TBST
The expression profile observed is consistent with what has been described in the literature (PMID: 20053998; PMID: 24933607).
Negative control: NIH/3T3, RAW264.7 whole cell lysates.
All lanes: Western blot - Anti-Tyrosinase antibody [EPR10141] (ab170905) at 1/1000 dilution
Lane 1: B16-F0 (mouse melanoma epithelial-like cell), whole cell lysate at 20 µg
Lane 2: B16-F10 (mouse melanoma epithelial-like cell), whole cell lysate at 20 µg
Lane 3: NIH/3T3 (mouse embryonic fibroblast), whole cell lysate at 20 µg
Lane 4: RAW264.7 (mouse Abelson murine leukemia virus-induced tumor macrophage), whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Predicted band size: 60 kDa
Observed band size: 50-80 kDa
Exposure time: 59s
Image collected and cropped by CiteAb under a CC-BY license from the publication
Tyrosinase western blot using anti-Tyrosinase antibody [EPR10141] ab170905. Publication image and figure legend from Jessen, C., Kreß, J. K. C., et al., 2020, Oncogene, PubMed 32978520.
ab170905 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab170905 please see the product overview.
Suppression of differentiation features by NRF2.a Immunoblot of NRF2 and COX2 in UACC-62 NFE2L2 wt and NFE2L2 knockout cells after TNFα treatment (50 ng/ml, 3 d). Vinculin served as loading control. b Corresponding real-time PCR of PTGS2 gene expression, derived from two independent experiments. c Linear regression analysis of MITF and PTGS2 mRNA (n = 472) (Adj R2 = 0.076577 Intercept = 4.4372 Slope = −0.20477 p = 5.7562e-10). The results shown here are based upon data derived from the TCGA dataset Skin Cutaneous Melanoma, and FPKM values were downloaded from www.cbioportal.org. d Protein blot of NRF2 and MITF in UACC-62 cells after knockdown of NFE2L2 for 3 d with two independent siRNAs. MITF is represented by both visible bands (arrows). e Expression changes of pigmentation genes after NFE2L2 knockdown in UACC-62 cells, as detected by RNA sequencing, using the siRNA N2. f Protein blot of TYR and MLANA in UACC-62 cells after knockdown of NFE2L2 for 3 d with two independent siRNAs. g Luciferase assay of UACC-62 cells after MITF induction (100 or 250 ng/ml, 3 d) and co-transfection with 400 ng or 800 ng of pcDNA3.1-NRF2 and a tyrosinase promoter construct for 2 d. Luciferase activity was measured twice in duplicates. h Immunoblot of NRF2 and MITF after doxycycline-dependent NRF2 induction in UACC-62 cells (1000 ng/ml Dox, 3 d). Actin served as loading control. i Immunoblot of MITF and COX2 in UACC-62 cells expressing the Dox-inducible MITF expression vector pSB-MITF. Where indicated, cells were treated with doxycycline (250 ng/ml, 3 d) and H2O2 was added for the last 5 h before harvesting (400 µM). j Corresponding real-time PCR of PTGS2. Data are derived from two independent experiments performed in duplicates. Error bars represent SD.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com